Brief: Candel Therapeutics Q3 Net Income USD -11.269 Million
13/11/2025 13:25
Nov 13 (Reuters) - Candel Therapeutics Q3 income from operations USD -13.207 million vs. IBES estimate USD -11.8 million. Q3 basic EPS USD -0.21 Q3 operating expenses USD 13.207 million
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Candel Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Candel Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights
Candel Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)